MHRA launches campaign to raise awareness over DMAA

The Medicines and Healthcare Regulatory Agency (MHRA) has launched a ‘Week of Action’ aimed at increasing awareness of unlicensed medicines which contain DMAA, a dietary supplement used as a pre-workout stimulant.

DMAA, or 1,3-dimethylamylamine, is a neural stimulant which can be dangerous to the body if consumed in significant amounts. In particular, researchers have found that the drug can cause high blood pressure, a side-effect which can be potentially fatal to those already experiencing hypertension.

MHRA’s DMAA week of action, starting 30 January - 5 February, will encourage consumers of sports supplements to check if their products contain DMAA by checking the global DRO list, which also identifies alternative names of the ingredient.

The campaign will also involve an animated social media campaign, with health & fitness bloggers sharing their stories and a video with Dr Chris Jones and weightlifters.

British Weightlifting, UK Anti-Doping, ESSNA, UK Active, National Food Crime Unit and Sporting Integrity Ltd have all voiced their support of the move.

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho